scholarly journals Diabetic Mastopathy in a Patient with High Risk of Breast Carcinoma: A Management Dilemma

Cureus ◽  
2020 ◽  
Author(s):  
Salsabeel S Alkhudairi ◽  
Mohammed M Abdullah ◽  
Ahmed G Alselais
Keyword(s):  
High Risk ◽  
Breast Carcinoma ◽  
Diabetic Mastopathy

Randomized trial of high-dose chemotherapy and autologous hematopoietic stem cell support for high-risk primary breast carcinoma

Cancer ◽  
2006 ◽  
Vol 106 (11) ◽  
pp. 2327-2336 ◽  
Author(s):  
Emer O. Hanrahan ◽  
Kristine Broglio ◽  
Deborah Frye ◽  
Aman U. Buzdar ◽  
Richard L. Theriault ◽  
...  
Keyword(s):  
Stem Cell ◽  
High Risk ◽  
Breast Carcinoma ◽  
Randomized Trial ◽  
High Dose Chemotherapy ◽  
High Dose ◽  
Primary Breast Carcinoma ◽  
Hematopoietic Stem ◽  
Stem Cell Support ◽  
Cell Support

Diabetic mastopathy: Differential diagnosis of breast carcinoma

2020 ◽  
Vol 26 (7) ◽  
pp. 1416-1417
Author(s):  
Marta Allué ◽  
Maria Dolores Arribas ◽  
Antonio Guemes
Keyword(s):  
Differential Diagnosis ◽  
Breast Carcinoma ◽  
Diabetic Mastopathy

Triple blinded prospective study assessing the impact of genomics: EndoPredict and artificial intelligence Watson for Oncology (WFO) on MDT’s decision of adjuvant systemic therapy for hormone receptor positive early breast carcinoma.

2019 ◽  
Vol 37 (15_suppl) ◽  
pp. e18013-e18013
Author(s):  
S.P. Somashekhar ◽  
Ramya Yethadka ◽  
Rohit Kumar C ◽  
Ashwin K Rajgopal ◽  
Amit Rauthan ◽  
...  
Keyword(s):  
Artificial Intelligence ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Breast Carcinoma ◽  
Systemic Therapy ◽  
Adjuvant Systemic Therapy ◽  
Tumor Board ◽  
Genomic Test ◽  
Board Decision ◽  
Early Breast Carcinoma

e18013 Background: : Decision on adjuvant systemic therapy in hormone positive early breast carcinoma is the only grey area in breast carcinoma management. This study was done to investigate the concordance between the results of genomic test, artificial intelligence and tumor board decision and implications of the same in clinical practice. Methods: This was a triple blinded, prospective study. Decision regarding the adjuvant systemic therapy was done by the multidisciplinary tumor board (MDT)after reviewing the pathology reports & the results correlated with Endopredict test reports & artificial intelligence(Watson for Oncology). Results: Total of 42 patients included. Mean age was 58.3 years, 71.4% were post-menopausal. Breast conservation was done in 47.6%. 64.2% were T1-2N0 stage. Infiltrating ducal carcinoma was major type (83.3%). Decision by MDT to give adjuvant chemotherapy was for 25 patients (59.5%) & hormonal therapy for rest. Recommendation by Watson for oncology was to give adjuvant chemotherapy in 50%. Endopredict score (EPclin) resulted in a low-risk group of 22 patients (52.3%), while 15(47.6%) had a high risk EPclin score. Discordance between the endopredict test, Watson & tumor board was for 11 patients (26.1%): 3 patients had high risk score, but the tumor board decision was to give hormonal therapy due to the age factor. 8 patients had low risk score, but tumor board decision was to give adjuvant chemotherapy. Extremes of age, premenopausal status, intermediate grade & high Ki 67% values were the factors associated with discordance. The treatment decision changed for 4 patients (4/11, 36%) after reviewing the endopredict test and Watson recommendation. Conclusions: Tumor board decision can be more scientific & evidence based with the help of genomics & a learnt colleague in the form of Watson for Oncology. Even though the clinical experience is the important determinant of adjuvant therapy, genomic test with artificial intelligence, which includes the scientific evidence, will guide in decision making. Long term follow up is needed for the validation in our clinical setting.

Sign in / Sign up

Export Citation Format

Share Document